NCT05325346View on ClinicalTrials.gov

A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

April 1, 2022

Study Completion Date

April 14, 2022

Conditions
Heparin-induced Thrombocytopenia
Interventions
DRUG

VLX-1005

Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD

DRUG

Argatroban

Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD

Trial Locations (1)

68502

Celerion, Inc., Lincoln

Sponsors

Collaborators (1)

Celerion
All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

Veralox Therapeutics

INDUSTRY

NCT05325346 - A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects | Biotech Hunter | Biotech Hunter